284 related articles for article (PubMed ID: 16936952)
1. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
[TBL] [Abstract][Full Text] [Related]
2. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
Oliveira FC; Oliveira GC; Cariello AJ; Felberg S; Osaki MH
Arq Bras Oftalmol; 2010; 73(5):405-8. PubMed ID: 21225122
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
Ababneh OH; Cetinkaya A; Kulwin DR
Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
[TBL] [Abstract][Full Text] [Related]
4. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
[TBL] [Abstract][Full Text] [Related]
5. Tear production and drainage after botulinum toxin A injection in patients with essential blepharospasm.
Park DI; Shin HM; Lee SY; Lew H
Acta Ophthalmol; 2013 Mar; 91(2):e108-12. PubMed ID: 23425111
[TBL] [Abstract][Full Text] [Related]
6. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
Gunes A; Demirci S; Koyuncuoglu HR; Tok L; Tok O
Cornea; 2015 Aug; 34(8):906-10. PubMed ID: 26075455
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin A treatment in patients suffering from blepharospasm and dry eye.
Horwath-Winter J; Bergloeff J; Floegel I; Haller-Schober EM; Schmut O
Br J Ophthalmol; 2003 Jan; 87(1):54-6. PubMed ID: 12488263
[TBL] [Abstract][Full Text] [Related]
8. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
Yabiku MM; Sartori Jde F; Sarraff EP; Osaki TH; Hossaka SK; Pereira CI; Freitas Wd; Osaki MH; Cariello AJ
Arq Bras Oftalmol; 2011; 74(6):414-6. PubMed ID: 22331113
[TBL] [Abstract][Full Text] [Related]
9. Five-Year Retrospective Review of Cases with Benign Essential Blepharospasm and Hemifacial Spasm Presenting in a Tertiary Eye Care Center in North India.
Raj A; Arya SK; Deswal J; Bamotra RK
Semin Ophthalmol; 2017; 32(3):371-376. PubMed ID: 27078720
[TBL] [Abstract][Full Text] [Related]
10. [Botulinum toxin therapy for focal dystonia].
Hahn K; Niklai E; Garzuly F; Szupera Z
Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
[TBL] [Abstract][Full Text] [Related]
11. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
[TBL] [Abstract][Full Text] [Related]
12. Pain relief in patients receiving periocular botulinum toxin A.
Harrison AR; Erickson JP; Anderson JS; Lee MS
Ophthalmic Plast Reconstr Surg; 2008; 24(2):113-6. PubMed ID: 18356715
[TBL] [Abstract][Full Text] [Related]
13. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
Bayraktar Bilen N; Bilen Ş; Topçu Yılmaz P; Evren Kemer Ö
Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
[TBL] [Abstract][Full Text] [Related]
14. Use of Alleviating Maneuvers for Periocular Facial Dystonias.
Kilduff CL; Casswell EJ; Salam T; Hersh D; Ortiz-Perez S; Ezra D
JAMA Ophthalmol; 2016 Nov; 134(11):1247-1252. PubMed ID: 27606483
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of blepharospasm, hemifacial spasm and facial synkinesis with botulinum toxin].
Winterhoff J; Laskawi R
HNO; 2012 Jun; 60(6):479-83. PubMed ID: 22669435
[TBL] [Abstract][Full Text] [Related]
16. Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study.
Pellegrini M; Schiavi C; Taroni L; Sebastiani S; Bernabei F; Roda M; Moscardelli F; Giannaccare G
Indian J Ophthalmol; 2019 Sep; 67(9):1405-1409. PubMed ID: 31436182
[TBL] [Abstract][Full Text] [Related]
17. Effect of Botulinum toxin A application in neuro-ophtalmologic indications on Schirmers test and tears osmolarity.
Žiak P; Halička J; Kapitánová K; Mojžiš P
Cesk Slov Oftalmol; 2019; 75(2):74-77. PubMed ID: 31537075
[TBL] [Abstract][Full Text] [Related]
18. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm.
Jost WH; Kohl A
J Neurol; 2001 Apr; 248 Suppl 1():21-4. PubMed ID: 11357234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
